New antibiotic could treat drug-resistant gonorrhea, study says
The drug, called gepotidacin, works by preventing bacteria from replicating in the body and was approved by the Food and Drug Administration in March to treat uncomplicated urinary tract infections in women and in girls 12 years and older.
If approved to treat gonorrhea, it will be the newest antibiotic to treat the sexually transmitted infection since the 1990s.
The drug is manufactured by the pharmaceutical company GSK and is sold under the name Blujepa.
After reaching a historic low in 2009, cases of gonorrhea in the United States steadily increased until 2021 and have slowly declined since then, according to the Centers for Disease Control and Prevention (CDC).
Still, gonorrhea is the second most common sexually transmitted infection in the country with 601,319 reported cases in 2023, according to the agency.
Gonorrhea, and other STIs, are becoming more difficult to treat as they become increasingly more resistant to existing antibiotics.
The CDC currently recommends providers treat gonorrhea with a 500 mg injection of the antibiotic ceftriaxone. The agency updated its treatment guidelines in 2023, directing providers to administer a higher dose of the drug to combat antibiotic resistance.
Justin Gill, an urgent care nurse practitioner and president of the Washington State Nurses Association, told The Hill that he frequently treats gonorrhea and has encountered cases of the infection that are resistant to ceftriaxone.
'There are only a handful of antibiotics that are available as backup options,' he said. 'The development of new antibiotics has been slow, but federal investment in new and emerging antibiotic options is necessary before resistant strains of gonorrhea expand further.'
If left untreated, gonorrhea can cause serious health complications which can lead to infertility in both men and women, as well as increasing the odds of contracting and passing HIV, according to the CDC.
The trial of more than 620 people showed gepotidacin was about 92 percent effective in treating the infection among those who took the drug twice a day. Meanwhile, a regimen of combination ceftriaxone and azithromycin was about 91 percent effective.
Stuart Ray, an infectious disease professor at Johns Hopkins University School of Medicine who did not take part in the study, said that any progress in safely and effectively treating gonorrhea is 'exciting.' He added that the fact that the drug can be administered in pill form makes it 'attractive.'
'In general, it's very exciting to see a late-stage trial for a new antimicrobial for a thorny problem like gonorrhea,' he said. 'I think it's very exciting to see data and progression of an agent this far down the path.'
Ray said that of the more than 600 trial participants, less than 10 percent were women.
'We have to be careful about making conclusions about subgroups that may have been somewhat underrepresented.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
The sober-curious generation? This map shows where Gen Z is reshaping U.S. drinking habits.
Gen Z is the sober-curious generation. Between 2011 and 2023, the number of adults aged 18 to 24 who drank alcohol dropped by 8 percentage points, according to survey data from the Centers for Disease Control and Prevention. Consumption among 25- to 34-year-olds has also fallen 5 percentage points over the past decade, making young adults the driving force behind America's diminishing alcohol consumption. Gen Z is driving the shift away from drinking. Even young people who do drink do so less frequently than previous generations. Nearly two-thirds of 18- to 34-year-olds say one to two drinks a day is bad for their health, reflecting changing attitudes toward drinking. These days, drinking less doesn't mean sacrificing a social life, though. Bars and liquor stores are catering to a growing demand for mocktails and zero-proof alcohol. Data from Eventbrite shows a 92% rise in sober-curious events across the country over the past year. These include everything from morning dance parties (20% rise) to DJ'd events with coffee instead of alcohol (478% rise). Advertisement Yahoo used data from Behavioral Risk Factor Surveillance System to examine the evolving drinking culture among young adults in the U.S. The map data is based on surveys conducted between 2011-2012 and 2022-2023.
Newsweek
4 minutes ago
- Newsweek
Bread Recall Sparks Highest Consumer Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of numerous bread products over potential undeclared allergens has received the highest risk warning from the Food and Drug Administration (FDA). Hillside Orchard Farms Inc., based in Georgia, issued a voluntary recall for the products on July 22 because of the possible undeclared presence of eggs. The FDA issued a Class I risk classification for the recall on August 20. Newsweek contacted Hillside Orchard Farms Inc. for comment by phone outside regular working hours. Why It Matters Eggs are one of the nine major food allergens as defined in law. The others are fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, sesame and milk. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. A stock image of a bread product. A stock image of a bread product. Torsten Sukrow/picture-alliance/dpa/AP What To Know A Class I risk classification represents "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death," according to the FDA. The agency warned in its recall notice, "People who have an allergy or severe sensitivity to egg run the risk of serious or life-threatening allergic reaction if they consume these products." These are the products affected by the recall: Apple Bread—product number: 1001 Apple Fritters—product number: 1051 Banana Nut Bread—product number: 1016 Blackberry Bread—product number: 1014 Blueberry Bread—product number: 1013 Blueberry Fritters—product number: 1063 Cheese Bread—product number: 1017 Cinnamon Pecan Bread—product number: 1012 Cinnamon Pecan Fritters—product number: 1062 Jalapeño Cheese Bread—product number: 1018 Peach Bread—product number: 1002 Peach Fritters—product number: 1052 Strawberry Bread—product number: 1011 Strawberry Fritters—product number: 1061 The products had use-by dates through July 23 and were distributed between November 18, 2024, and July 16, 2025. The products were sold primarily in farm markets and on roadside stands in Alabama, Georgia, North Carolina, Pennsylvania and South Carolina. The company initiated the recall after an FDA investigation found that the product labels failed to include the allergen egg. As of July 28, no illnesses had been reported in connection with the consumption of the recalled products. What People Are Saying The FDA said on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." What Happens Next The recall is listed as ongoing, according to the FDA. Consumers who purchased the affected products are urged to return them to their place of purchase for a full refund.
CNN
4 minutes ago
- CNN
At least 600 CDC employees are getting final termination notices, union says
At least 600 employees of the Centers for Disease Control and Prevention are receiving permanent termination notices in the wake of a recent court decision that protected some CDC employees from layoffs but not others. The notices went out this week and many people have not yet received them, according to the American Federation of Government Employees, which represents more than 2,000 dues-paying members at CDC. The U.S. Department of Health and Human Services on Wednesday did not offer details on the layoffs and referred an AP reporter to a March statement that said restructuring and downsizing were intended to make health agencies more responsive and efficient. AFGE officials said they are aware of at least 600 CDC employees being cut. But 'due to a staggering lack of transparency from HHS,' the union hasn't received formal notices of who is being laid off,' the federation said in a statement on Wednesday. The permanent cuts include about 100 people who worked in violence prevention. Some employees noted those cuts come less than two weeks after a man fired at least 180 bullets into the CDC's campus and killed a police officer. 'The irony is devastating: The very experts trained to understand, interrupt and prevent this kind of violence were among those whose jobs were eliminated,' some of the affected employees wrote in a blog post last week. On April 1, the HHS officials sent layoff notices to thousands of employees at the CDC and other federal health agencies, part of a sweeping overhaul designed to vastly shrink the agencies responsible for protecting and promoting Americans' health. Many have been on administrative leave since then — paid but not allowed to work — as lawsuits played out. A federal judge in Rhode Island last week issued a preliminary ruling that protected employees in several parts of the CDC, including groups dealing with smoking, reproductive health, environmental health, workplace safety, birth defects and sexually transmitted diseases. But the ruling did not protect other CDC employees, and layoffs are being finalized across other parts of the agency, including in the freedom of information office. The terminations were effective as of Monday, employees were told. Affected projects included work to prevent rape, child abuse and teen dating violence. The laid-off staff included people who have helped other countries to track violence against children — an effort that helped give rise to an international conference in November at which countries talked about setting violence-reduction goals. 'There are nationally and internationally recognized experts that will be impossible to replace,' said Tom Simon, the retired senior director for scientific programs at the CDC's Division of Violence Prevention.
